At least nine companies reduced their workforces during the second quarter, compared to at least six in the same period last year. All cash and operating loss figures in $M. (A) 12-month operating loss at Dec. 31, 2011

Date

Company

Staff cuts

Cash

Yrs cash pre-cut

Cash date

3-mo op loss ended 3/31

4/16/12

Addex Therapeutics (SIX:ADXN)

31% to 54

$39.3

1.17

12/31/11

$33.7 (A)

Restructuring for the second time in nine months to reduce costs following the termination of two licensing deals by Merck & Co. Inc. (NYSE:MRK); expects to extend cash reach into 4Q13; Addex's dipraglurant-IR is in Phase II testing to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID)

4/16/12

WaferGen BioSystems Inc. (OTCBB:WGBS)

38% to 33

$12.0

0.86

3/31/12

$3.5

Focusing on SmartChip Real-Time PCR System, which profiles and validates gene expression patterns; expects a monthly burn rate of about $700,000